The global custodian’s tech needs are moving from the back office to the front, says its Hong Kong head.

The post Northern Trust seeks fintech help for ESG appeared first on Digital Finance.

Hamilton, Bermuda, Mar 4, 2022 - (ACN Newswire) - Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Under the terms of the Agreement, Altamira will initially supply Bentrio(TM) to Nuance. Nuance will make an upfront payment of $1 million and pay to Altamira development and commercial milestones of up to $3 million and up to $19.5 million, respectively. Nuance will have the right to register and commercialize Bentrio(TM) in the Territory. In a second stage, Nuance will assume local production of the product for the Territory upon certain milestones. Once Nuance assumes local production of Bentrio(TM), it will pay to Altamira a staggered royalty on net sales in the Territory at a high-single to low-double-digit percentage.

"We are excited to greatly expand the distribution of Bentrio and further enlarge our footprint in Asia through this strategic collaboration with Nuance," said Thomas Meyer, Altamira Therapeutics' founder, Chairman and CEO. "As a fast growing, well capitalized company with a growing portfolio of products specifically for the treatment of respiratory disorders, Nuance is an ideal commercialization partner for this important and dynamic region. We are looking forward to working with the Nuance team to launch Bentrio."

"The prevalence of allergic rhinitis in the Chinese Mainland is particularly high, affecting some 246 million patients[1]," commented Mark G. Lotter, CEO and Founder of Nuance. "In addition, viral infections represent another high-volume opportunity for Bentrio in this region, so we are looking forward to launching this promising therapeutic to patients in the Chinese Mainland; as well as Hong Kong, Macau and South Korea. Bentrio(TM) fits well with Nuance's continuous strategic focus in respiratory space."

References
[1] https://doi.org/10.4168/aair.2019.11.2.156

About Bentrio(TM)

Bentrio(TM)(AM-301) is a drug-free nasal spray intended for personal protection against airborne viruses and allergens. Upon application into the nose, Bentrio(TM) forms a protective gel layer on the nasal mucosa. This thin film is designed to prevent the contact of viruses or allergens with cells; in addition, the composition serves to bind such particles and help with their discharge and to humidify the nasal mucosa. Together, this is designed to reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms. In human nasal epithelium cells infected by SARS-CoV-2, Bentrio(TM) was shown to reduce the infectious viral load by more than 99% when used for prevention. Further, Bentrio(TM) was effective in slowing the growth of the viral titer when treatment started only 24 or 30 hours after infection. In allergy, a clinical investigation in a pollen challenge chamber demonstrated a significant reduction in the main symptoms of allergic rhinitis with the protective effect setting in rapidly and lasting for 4 hours.

About Nuance Pharma

Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance has built a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation. Focusing on specialty care, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, emergency care, and iron deficiency anemia. Through partnerships with global leading biopharma companies, Nuance has built a leading late-stage portfolio in respiratory and commercial stage portfolio in emergency care and iron deficiency anemia.

About Altamira Therapeutics

Altamira Therapeutics is dedicated to developing therapeutics that address important unmet medical needs. The Company is currently active in three areas: the development of RNA therapeutics for extrahepatic therapeutic targets (OligoPhore(TM) / SemaPhore(TM) platforms; preclinical), nasal sprays for protection against airborne viruses and allergens (Bentrio(TM); commercial) or the treatment of vertigo (AM-125; Phase 2), and the development of therapeutics for intratympanic treatment of tinnitus or hearing loss (Keyzilen(R) and Sonsuvi(R), Phase 3). The Company was founded in 2003 and is headquartered in Hamilton, Bermuda with its main operations in Basel, Switzerland. The shares of Altamira Therapeutics Ltd. trade on the NASDAQ Capital Market under the symbol "CYTO."

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Altamira Therapeutics' strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the approval, timing of commercialization and commercial success of AM-301, Altamira Therapeutics' need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Altamira Therapeutics' product candidates, the clinical utility of Altamira Therapeutics' product candidates, the timing or likelihood of regulatory filings and approvals, Altamira Therapeutics' intellectual property position and Altamira Therapeutics' financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Altamira Therapeutics' capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Altamira Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2020, and in Altamira Therapeutics' other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward-looking statements attributable to Altamira Therapeutics or to persons acting on behalf of Altamira Therapeutics are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Altamira Therapeutics does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

Investor contact:
Stephen Kilmer
(647) 872-4849
[email protected]

SOURCE: Altamira Therapeutics Ltd.

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comAltamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, announced today that it has entered into an exclusive licensing and distribution agreement (the "Agreement") for Bentrio(TM), its nasal spray for protection against airborne viruses and allergens, with Nuance Pharma Ltd. ("Nuance") in Chinese Mainland, Hong Kong, Macau and South Korea (the "Territory").

Fans of the globally popular anime Sword Art Online can immerse themselves in exhibits inspired by the series through March 10. #ad

HONG KONG, Feb 23, 2022 - (ACN Newswire) - UMP Healthcare Holdings Limited ("UMP" or the "Group"; SEHK: 722) has announced that its affiliate, UMP Charity Foundation Limited (the "Charity Foundation"), will donate first batch of donation of HK$500,000 to support patients diagnosed with COVID-19 through the provision of free medical video consultation, or 'telemedicine' services and the expansion of the Sinovac vaccination service at the Group's medical centres. It is anticipated that at least 10,000 people in need will benefit from these services in the next month. An additional donation may be committed when needed.
As the number of new COVID-19 cases rapidly increases, patients with confirmed infections are stuck at home waiting for hospital admission or in isolation, and many elderly people, adults, and children urgently need medical consultations. UMP will provide free telemedicine services for relevant patients in response to current needs and the Hospital Authority's call to support anti-epidemic efforts. Patients who have been confirmed infections, preliminary infections or have self-tested positive using rapid antigen tests can register online for the service. A video consultation with a doctor will be arranged during designated service hours and they will be provided with any required medication if necessary. The consultation could help to alleviate patients' concern and enable them to receive treatment without leaving their home. Donations from the Charity Foundation will fully subsidise the costs of the consultation services, medicine and support for all related matters.

In addition, given the rapid increase of vaccination demand, 11 of the Group's medical centres are gearing up to support the Sinovac vaccination service. UMP will also set up an additional vaccination point at the UMP Wellness & Metabolic Centre in Central to provide extra services for seniors and children, who are considered priority groups for protection. There will be specialist doctors and registered nurses in attendance at the centre to evaluate those who wish to be vaccinated and confirm their recommendations. They will also answer questions and follow up with those who have received the vaccination, reducing anxiety and worries of those in need.

Dr. Sun Yiu Kwong, Chairman and CEO of UMP, and Director of UMP Charity Foundation, said, "UMP hopes to fulfil its responsibilities as a corporate and professional medical institution to help the public amid the severe epidemic in Hong Kong. Our medical team is also ready to do its best to reduce the pressure on the public medical system, provide support to those in need and have a positive impact on society. Meanwhile, we express our condolences to those affected by the epidemic and hope that our actions can provide immediate warmth."

Telemedicine service hours are Monday to Friday, 9am to 6pm, with limited service available in the evenings and Saturdays. To register, please visit https://bit.ly/3H2IzY8.

Sinovac vaccination services are provided at the following locations. Service hours vary by individual centre. For enquiries, please call the respective medical centre.

UMP Medical Centre (Central)
Address: 14/F, Wing On House, 71 Des Voeux Road Central
Phone: (852) 2840 1636

UMP Wellness & Metabolic Centre (for seniors and children)
Address: Room 1603, 16/F, Wing On House, 71 Des Voeux Road Central
Phone: (852) 2507 2656

UMP Medical Centre (Causeway Bay)
Address: Room 1901C, 19/F, East Point Centre, 555 Hennessy Road, Causeway Bay
Phone: (852) 2811 8218

UMP Medical Centre (Wanchai)
Address: Room 1109, Office Tower, Convention Plaza, 1 Harbour Road, Wan Chai
Phone: (852) 2824 0018

UMP Medical Centre (Jordan)
Address: Room 03-04, 15/F, 238 Nathan Road, Jordan
Phone: (852) 3549 6833

UMP Medical Centre (Tsim Sha Tsui)
Address: Room 7, 10/F, Wing On Plaza, 62 Mody Road, Tsim Sha Tsui East
Phone: (852) 2369 9536

UMP Medical Centre (Olympic)
Address: Unit 2, 1/F, Skyway House,3 Sham Mong Road, Taikoktsui
Phone: (852) 2740 4319

UMP Medical Centre (Kwun Tong)
Address: G/F, 183 Hip Wo Street, Kwun Tong
Phone: (852) 2855 8098

UMP Medical Centre (Kowloon Bay)
Address: Shop F, G/F, Tak Bo Garden, 3 Ngau Tau Kok Road, Kowloon Bay
Phone: (852) 2751 9339

UMP Medical Centre (Tsuen Wan)
Address: Shop 1070, Level 1, D-PARK, 398 Castle Peak Road, Tsuen Wan
Phone: (852) 2940 1338

UMP Medical Centre (Shatin)
Address: Shop 9, G/F, Ming Yiu Lau, Jat Min Chuen, Shatin
Phone: (852) 2634 1812

UMP Medical Centre (Park Island)
Address: G/F, No.21 Ma Wan Main Street Village East, Ma Wan
Phone: (852) 2986 3880

About UMP Healthcare
www.ump.com.hk

Founded in 1990, UMP Healthcare Holdings Limited is one of the largest and longest listed medical groups in Hong Kong, and is listed on the main board of the Hong Kong Stock Exchange (stock code: 722.HK). The company has been providing trusted and affordable medical services for 32 years, giving people peace of mind to focus on living their lives to the fullest without worrying about their health. The company is committed to helping people improve their health and winning the fight against the epidemic together.

In addition to healthcare services that cater to diverse individual needs, UMP works closely with corporates and insurance companies to customize and administer corporate healthcare benefits plans for their members. The current UMP network boasts more than 1100 self-owned and affiliated medical service points across Hong Kong and Macau, providing services including family medicine, specialist consultation, dental care, diagnostic imaging and laboratory, preventive medicine and health assessment, day surgery and endoscopy.



Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comUMP Healthcare Holdings Limited ("UMP" or the "Group"; SEHK: 722) has announced that its affiliate, UMP Charity Foundation Limited (the "Charity Foundation"), will donate first batch of donation of HK$500,000 to support patients diagnosed with COVID-19 through the provision of free medical video consultation

The post Sony Hosting an Official ‘Sword Art Online’ Exhibition in VR Through March 10th appeared first on Road to VR.

Sword Art Online is heading to VR in a special limited-time event that kicks off this week exclusively online. Starting tomorrow fans of the critically-acclaimed animated series Sword Art Online (SAO) can log into Sword Art Online -EX-CHRONICLE- Online Edition and explore a sprawling virtual world featuring memorable locations from the show. Attendees begin their […]

The post Sword Art Online VR Event Immerses You In The Hit Anime appeared first on VRScout.

A must for any SAO fan.

In recent years, esports have become more and more popular as the younger generations champion such play. With esports now being broadcast live...

Tokyo, Japan, Feb 14, 2022 - (ACN Newswire) - Quantum FOMM Limited ("QF"), a subsidiary of Quantum Solutions ("Quantum") and a joint venture with FOMM Corporation ("FOMM"), announced on 31 January 2022 that it has entered into a Framework Agreement ("Agreement") with FOMM for the manufacturing and distribution of FOMM One, FOMM's first electric vehicle model and one of Japan's few approved EV kei car on the road today. This Agreement solidifies Quantum's entry into the EV sector, laying the groundwork to become a leader in quality, affordable, micro-EV.

Through this Agreement, FOMM grants QF the exclusive licensing rights for the manufacturing and sales of FOMM One, along with all necessary intellectual property rights, in the countries and regions of China (including Hong Kong, Macau and Taiwan), Malaysia, Singapore, Indonesia, and Latin America. In FOMM One's existing markets of Japan and Thailand, QF will partner with existing dealers for distribution of the vehicles.

Based in Kanagawa Prefecture, FOMM was founded in 2013 by a team of auto engineers who had previously developed electric vehicles at Suzuki Motor Corporation. Over the years, FOMM developed its first micro, electric four-seater kei car model, FOMM One, to cater to the specific needs of the Japanese market.

Specifically, in Japan, kei means "light", and these vehicles are known for their affordability and small engines. The category makes up about a third of new domestic automobile sales annually, as the vehicles are a popular means of transportation especially in rural areas, where public transport systems are sparse and roads are narrow. While FOMM One is geared towards general consumers in the kei car category, demand is also expected from local governments, commercial businesses such as logistics company, ride-shares and more. As the Japanese government pledges to decarbonize Japan by 2050 with plans to ban the sale of new gasoline-only vehicles by mid-2030's, FOMM One is well positioned for market share growth in the Japanese car market.

Beyond Japan, Quantum and QF plans to expand its footprint to select ASEAN and Latin America cities where national and local governments are embracing affordable and sustainable mobility solutions in unprecedented ways. Compensation of such rights is 200 million JPY, as announced in the "Notification for Change in Use of Funds from 8th Series of Stock Acquisition Rights." Quantum plans to raise 175 million JPY through the Series 8 Stock Acquisition Rights and allocate the remaining 25 million JPY from cash on hand.

About Quantum Solutions Limited (2338.T)
Quantum Solutions is a Tokyo Stock Exchange listed company engaged in the EV sector.

About Quantum FOMM Limited
Incorporated in Hong Kong, Quantum FOMM is a subsidiary of Quantum Solutions and a joint venture with FOMM Corporation. The joint venture is designated for EV business of Quantum.

About FOMM Corporation
Based in Kanagawa prefecture of Japan and established in 2013, FOMM is an R&D and design-oriented mobility company specializing in planning and developing compact mobility using innovative designs and technologies.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comQuantum FOMM Limited ("QF"), a subsidiary of Quantum Solutions ("Quantum") and a joint venture with FOMM Corporation ("FOMM"), announced on 31 January 2022 that it has entered into Framework Agreement with FOMM for the manufacturing and distribution of FOMM One, FOMM's first electric vehicle model and one of Japan's few approved EV kei car on the road today.

Senator Pat Toomey, a senior member of the U.S. Senate Banking Committee, urges the Treasury and State Departments closely examine Beijing’s CBDC rollout during the Olympic Games. (Read More)

China announced 15 pilot zones for testing the application of blockchain technology for several service sectors. (Read More)

Global payments network Thunes announced plans to significantly accelerate the expansion of its operations in Greater China, spanning mainland China, Hong Kong, Taiwan, and Macau. This news follows the recent

The post Thunes to Scale up Its Operations in the Greater China appeared first on Fintech Singapore.